Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Oral Probiotic Lp299v Treats Symptoms Associated with IBS - Nutraceuticals World

What are you searching for?

Sign in
Products & Ingredients

Oral Probiotic Lp299v Treats Symptoms Associated with IBS

Author Image

By: Sean Moloughney

Editor, Nutraceuticals World

Results of a study presented in May at Digestive Disease Week (DDW) by Professor Philippe Ducrotté, from Rouen University Hospital, in France, demonstrated that the probiotic strain Lactobacillus plantarum 299v (LP299v) effectively relieves gastrointestinal symptoms, particularly abdominal pain and bloating, in Irritable Bowel Syndrome (IBS) patients fulfilling the Rome III criteria.

 
The randomized, placebo-controlled trial enrolled 214 patients (63 women and 151 men) fulfilling the Rome III criteria for IBS. The study was conducted over a four-week period and consisted of a daily capsule of placebo or Lp299v equivalent to 10 CFU/day. IBS symptoms were monitored, including frequency of abdominal pain, intensity of abdominal pain, bloating, number of stools and feeling of incomplete rectal evacuation.
 
After four weeks of treatment, Lp299v significantly improved the symptoms, in particular abdominal pain and bloating, as compared to both baseline and the placebo group. The overall patient’s assessment of the treatment was significantly better in the Lp299v group compared to the placebo group.
 
Jarrow Formulas’ Ideal Bowel Support 299v contains Probi’s proprietary probiotic strain Lactobacillus plantarum 299v (Lp299v), which has been shown in clinical trials to survive and colonize the digestive tract and alleviates intestinal discomfort in 95% of the patients studied.

Add us as a preferred source on Google

Get the latest Nutraceuticals World news, insights and analysis in your Google Search and AI experiences.

Add Nutraceuticals World as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Nutraceuticals World Newsletters